HPLC Assay Method Development and Validation for Quantification of Capecitabine in Tablets and Forced Degradation Samples

Year 2017, Volume: 21 Issue: 3, 660 - 668, 24.06.2017

M S Bhatıa J N Raut A C Barve P S Patıl S D Jadhav

https://doi.org/10.12991/marupj.323588

Abstract

A simple, rapid, accurate and stability indicating RP-HPLC

method was developed for the determination of Capecitabine

in pure and tablet dosage form. The mobile phase consisting

of 0.1% aqcetic acid, methanol and acetonitrile in the ratio of

35:60:5 v/v. The Inertsil ODS (octadecyl silane), C18, 3V, 250 x

4.6 mm, 5μm with UV detection 304 nm was used. The retention

time was found to be 6.4 minutes. The method was statistically

validated for accuracy, linearity, precision, robustness, specificity

and range. The method was found linear over the concentration

range of 50-150 μg/ml. The recovery studies of dosage form

were also carried out and analyzed; the % relative standard

deviation (RSD) from recovery studies was found to be within

limits. The specificity of the method was ascertained by forced

degradation studies by acid, alkali hydrolysis and oxidation.

About 35% of drug is degraded in acidic medium and less than

that in alkaline and oxidative conditions. Due to simplicity,

rapidity and accuracy of the method, the method will be useful

for routine analysis and checking purity of capecitabine tablet.

The method further can be investigated for pharmacokinetic

and biopharmaceutical analysis.

Keywords

Capecitabine, 5-fluorouracil, metastatic breast, colorectal cancer, RP-HPLC, ICH guidelines

References

• 1. The Merck Index, 6281, 13th edition. Merck research Laboratories. Merck & Co., Inc., USA. 2001, pp 1154. 2. United States Pharmacopoeia 32-National Formulary 27. 2009, pp 2148-2149. 3. Guichard SM, Mayer I, Jodrell DI. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies J Chromatogr B 2005; 826:232-7. 4. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications,pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46:171- 9. 5. Dooley M, Goa KL. Capecitabine. Drugs 1999; 58: 69-76. 6. Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of Capecitabine and its metabolites. Clin Cancer Rese 1999; 5: 1696-702. 7. Capecitabine. Available at ; https://pubchem.ncbi.nlm.nih. gov/compound/60953. 8. Hassanlou S, Rajabi M, Shahrasbi AA, Afshar M. Development and validation of an ecofriendly HPLC-UV method for determination of capecitabine in human plasma: Application to pharmacokinetic studies. S Afr J Chem 2016; 69: 174-9. 9. Deng P, Ji C, Dai X, Zhong D, Ding L, Chen X. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 989: 71-79. 10. Piórkowska E, Kaza M, Fitatiuk J, Szlaska I, Pawiński T, Rudzki PJ. Rapid and simplified HPLC-UV method with online wavelengths switching for determination of capecitabine in human plasma. Pharmazie 2014; 69: 500-5. 11. Deenen MJ, Rosing H, Hillebrand MJ, Schellens JHM, Beijnen JH. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 913- 914:30-40. 12. Montange, Berard M, Demarchi M, Muret P, Piédoux S, Kantelip JP, Royer B. An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma. J Mass Spectrom 2010; 45: 670-7. 13. Vainchtein LD, Rosing H, Schellens JHM, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5′-deoxy-5- fluorocytidine, 5′-deoxy-5- fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed Chromatogr 2010; 24: 374-86. 14. Švobaite R, Solassol I, Pin uet F, Mazard T, Ivanauskas L, Ychou M, Ressolle FMM. A liquid chromatography-mass spectrometry method for the simultaneous determination of capecitabine, 5′-deoxy-5-fluorocytidine, 5′-deoxy-5- fluorouridine, 5-fluorouracil, and 5-fluorodihydrouracil in human plasma. J Liq Chromatogr Relat Technol 2010; 33: 1705-19. 15. Licea-Perez H, Wang S, Bowen C. Development of a sensitive and selective LC-MS/MS method for the determination of α-fluoro-β-alanine, 5-fluorouracil and capecitabine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1040-6. 16. Singhal P, Shah PA, Shah JV, Sharma P, Shrivastav PS. Determination of capecitabine-an anticancer drug in dried blood spot by LC-ESI-MS/MS. Int J Pharm Pharm Sci 2015; 7: 238-45. 17. Ravisankar P, Devala Rao G, Naveen Kumar M, Krishna Chaitanya M. An improved RP-HPLC method for the quantitative determination of capecitabine in bulk and pharmaceutical tablet dosage form. Pharm Lett 2013; 5: 249- 60. 18. Kishore M, Jayaprakash M, Vijayabhaskarareddy T. Spectrophotometric determination of capecitabine in pharmaceutical formulations. Int J ChemTech Res 2011; 3: 63- 9. 19. Guichard SM, Mayer I, Jodrell DI. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 826: 232-7.